acylguanidin
new
class
antivir
compound
uniqu
abil
target
rna
polymeras
transmembran
protein
virus
differ
famili
importantli
inhibit
protein
target
exist
antivir
therapi
exampl
vpu
hiv
type
hepat
c
viru
e
sever
acut
respiratori
syndrom
coronaviru
rnadepend
rna
polymeras
coxsackieviru
develop
biotron
limit
first
acylguanidin
clinic
trial
hiv
type
hepat
c
viru
articl
focu
mechan
inhibit
viral
protein
acylguanidin
avail
treatment
viral
infect
limit
approxim
antivir
compound
approv
clinic
use
us
fda
target
hiv
mani
import
virus
antivir
treatment
avail
exist
treatment
limit
efficaci
develop
viru
resist
side
effect
current
strategi
combat
develop
drug
resist
combin
therapi
use
drug
target
differ
process
viru
replic
cycl
addit
use
differ
class
compound
target
process
eg
nucleosid
nonnucleosid
polymeras
inhibitor
although
mani
current
drug
discoveri
program
focus
find
new
combin
therapeut
also
ongo
search
compound
target
virus
treatment
current
avail
articl
highlight
antivir
action
acylguanidin
class
compound
remark
rang
inhibitori
target
cellular
viral
peculiar
compound
inhibit
divers
type
protein
henc
variou
process
viru
replic
cycl
acylguanidin
larg
class
chemic
contain
carbonylguanidino
moieti
prototyp
acylguanidin
amilorid
fig
potassiumspar
diuret
wide
use
medicin
first
describ
crago
et
al
primari
target
amilorid
epitheli
na
channel
inhibit
nanomolar
concentr
micromolar
concentr
amilorid
inhibit
sever
cellular
ion
transport
eg
na
h
exchang
enzym
receptor
epitheli
na
channel
import
target
treatment
hypertens
cystic
fibrosi
na
h
exchang
central
factor
growth
invas
properti
mani
cancer
cell
cell
damag
follow
myocardi
infarct
reason
numer
acylguanidin
increas
potenc
specif
toward
either
epitheli
na
channel
na
h
exchang
compar
amilorid
synthesis
acylguanidin
made
way
antivir
drug
develop
past
decad
base
known
activ
cellular
ion
channel
blocker
amilorid
deriv
test
viral
protein
possess
ion
channel
activ
one
compound
n
nhexamethylen
amilorid
hma
fig
shown
inhibit
ion
channel
protein
four
virus
belong
three
famili
vpu
protein
hiv
type
retrovirida
famili
protein
hepat
c
viru
hcv
protein
dengu
viru
flavivirida
famili
e
protein
sever
acut
respiratori
syndrom
coronaviru
coronavirida
famili
subsequ
drug
develop
program
produc
compound
current
clinic
trial
two
virus
differ
studi
demonstr
nonionchannel
protein
rnadepend
rna
polymeras
coxsackieviru
picornavirida
famili
also
inhibit
amilorid
deriv
vpu
protein
hiv
type
hiv
isol
group
two
type
type
type
domin
worldwid
agent
acquir
immunodefici
syndrom
wherea
restrict
region
western
central
africa
introduct
highli
activ
antiretrovir
therapi
treatment
paradigm
use
three
compound
combin
achiev
effici
inhibit
viru
replic
patient
howev
hiv
cure
global
preval
infect
stabilis
encod
nine
protein
requir
replic
manipul
host
one
accessori
protein
vpu
absent
establish
function
vpu
infect
cell
downregul
tetherin
also
known
tetherin
inhibit
viru
releas
incorpor
nascent
virion
crosslink
viral
cellular
membran
crucial
viru
entri
later
replic
cycl
inhibit
assembl
releas
infect
progeni
virion
interact
viral
glycoprotein
two
studi
demonstr
vpu
contribut
effici
spread
vivo
singh
et
al
infect
macaqu
chimer
simianhiv
express
either
wildtyp
vpu
mutat
vpu
downregul
anim
produc
wildtyp
vpu
maintain
significantli
higher
viral
load
produc
mutat
protein
suggest
downregul
vpu
contribut
pathogen
anoth
studi
sato
et
al
infect
humanis
mice
produc
human
leukocyt
includ
cell
wildtyp
vpudefici
show
wildtyp
viru
propag
rapidli
vpudefici
viru
furthermor
show
vpu
increas
releas
cellfre
virion
without
affect
celltocel
transmiss
vpu
acid
depend
viral
isol
membran
protein
consist
ntermin
transmembran
domain
ctermin
cytoplasm
domain
form
pentamer
cationselect
ion
channel
planar
lipid
bilay
studi
ewart
et
al
biotron
limit
show
ion
channel
form
vpu
transmembran
domain
block
amilorid
deriv
hma
n
ndimethyl
amilorid
dma
fig
amilorid
hma
also
shown
inhibit
bud
viruslik
particl
hela
cell
suggest
link
ion
channel
activ
vpu
viru
releas
subsequ
studi
demonstr
hma
dma
inhibit
replic
cultur
human
macrophag
ensu
program
chemic
synthesi
biotron
gener
librari
approxim
compound
lead
compound
fig
mm
concentr
complet
block
ion
channel
form
vpu
transmembran
domain
planar
lipid
bilay
reduc
yield
supernat
cultur
human
macrophag
effect
concentr
ec
mm
select
index
ratio
toxic
concentr
ec
reduct
yield
extracellular
lack
vpu
observ
condit
demonstr
vpu
inde
antivir
target
biotron
recent
start
stage
ibiia
clinic
trial
hivposit
treatmentna
patient
administ
drug
day
eight
patient
receiv
placebo
result
expect
first
quarter
biotron
http
wwwbiotroncomau
mechan
action
acylguanidin
elucid
prevail
hypothesi
inhibit
ion
channel
activ
vpu
howev
current
proof
ion
channel
activ
vpu
role
viru
replic
cycl
publish
data
suggest
requir
downregul
tetherin
vpu
mutant
without
ion
channel
function
retain
abil
downregul
tetherin
altern
acylguanidin
could
block
vpu
bind
cellular
target
howev
kuhl
et
al
recent
demonstr
interfer
vputetherin
interact
moreov
compound
inhibit
yield
tcell
line
without
affect
tetherin
modul
data
suggest
antivir
action
acylguanidin
inhibit
tetherin
downregul
vpu
potenti
effect
downregul
remain
investig
also
recent
studi
identifi
new
cellular
target
vpu
work
requir
determin
function
vpu
infect
cell
inhibit
acylguanidin
whether
inhibit
occur
blockad
ion
channel
activ
altern
mechan
protein
hcv
hcv
belong
genu
hepacivirus
flavivirida
famili
two
genera
famili
flavivirus
eg
dengu
viru
pestivirus
eg
bovin
viral
diarrhoea
viru
estim
world
popul
chronic
infect
hcv
lead
lifethreaten
liver
diseas
includ
hepatocellular
carcinoma
current
therapi
pegyl
interferon
ribavirin
effect
approxim
case
hcv
genom
encod
polyprotein
approxim
amino
acid
process
host
viral
proteas
least
ten
polypeptid
core
capsid
protein
two
envelop
protein
seven
nonstructur
protein
hcv
acid
membran
protein
compris
two
transmembran
domain
connect
basic
cytoplasm
loop
form
hexaand
heptamer
cationselect
channel
phospholipid
membran
requir
togeth
one
nonstructur
protein
effect
assembl
releas
infecti
viru
vivo
essenti
hcv
infect
chimpanze
ion
channel
nonionchannel
function
requir
product
infecti
viru
hcv
assembl
believ
occur
endoplasm
reticulum
er
viral
envelop
protein
accumul
recent
studi
boson
et
al
demonstr
colocalis
core
protein
envelop
protein
er
requir
effici
virion
assembl
strainspecif
factor
govern
intracellular
localis
core
protein
infect
cell
although
ion
channel
activ
appear
unlik
involv
core
protein
localis
crucial
intracellular
viru
viabil
extracellular
hcv
virion
acidresist
wherea
intracellular
viru
particl
greatli
increas
acid
sensit
proton
channel
activ
protect
intracellular
viru
particl
prevent
oblig
acidif
intracellular
compart
mutat
abrog
ion
channel
activ
result
complet
loss
infecti
viru
product
could
partial
restor
prevent
acidif
inhibitor
bafilomycin
sever
compound
inhibit
hcv
ion
channel
lipid
bilay
identifi
includ
hma
madindarbi
bovin
kidney
mdbk
cell
inhibit
bovin
viral
diarrhoea
viru
pestiviru
use
hcv
model
ec
nm
select
index
approxim
show
synergi
current
use
antihcv
drug
interferon
ribavirin
current
hypothesi
regard
mechan
antivir
activ
relat
inhibit
ion
channel
activ
remain
confirm
compound
recent
complet
stage
iia
clinic
trial
hepat
c
patient
randomli
assign
receiv
either
mg
mg
placebo
ratio
first
day
standard
treatment
interferon
ribavirin
preliminari
analysi
trial
data
show
approxim
tenfold
greater
viru
reduct
blood
patient
receiv
mg
dose
compar
receiv
interferon
ribavirin
biotron
http
wwwbiotroncomau
dengu
widespread
mosquitoborn
viral
diseas
year
million
dengu
infect
individu
hospitalis
dengu
haemorrhag
fever
mainli
southeast
asia
pacif
america
present
antivir
treatment
dengu
dengu
viru
genom
encod
polyprotein
cleav
three
structur
protein
c
prm
e
seven
nonstructur
protein
prm
acid
membran
protein
crucial
role
viru
assembl
matur
immatur
viru
particl
assembl
er
viral
nucleocapsid
form
protein
c
viral
genom
becom
envelop
lipid
membran
contain
prme
heterodim
viru
particl
transport
secretori
pathway
transgolgi
network
acid
environ
induc
conform
chang
follow
cleavag
prm
acid
pr
acid
result
matur
virion
contain
wherea
pr
remain
attach
virion
releas
extracellular
environ
thu
protect
e
fusion
intracellular
membran
function
unknown
premkumar
et
al
shown
peptid
correspond
ctermin
transmembran
domain
prmm
ion
channel
activ
planar
lipid
bilay
inhibit
hma
contrast
ion
channel
activ
observ
prm
express
xenopu
oocyt
despit
protein
localis
oocyt
surfac
thu
clear
whether
prm
form
ion
channel
antivir
activ
hma
dengu
virus
yet
shown
coronavirida
caus
respiratori
diseas
human
varieti
sever
diseas
anim
sever
acut
respiratori
syndrom
coronaviru
sarscov
jump
animalhuman
host
barrier
infect
peopl
caus
death
http
wwwwhointcsrsarscountri
sarscov
genom
encod
four
structur
protein
spike
membran
envelop
nucleocapsid
addit
nonstructur
eight
accessori
protein
acid
envelop
protein
e
embed
viru
lipid
envelop
togeth
spike
membran
protein
cell
cultur
titr
sarscov
lack
e
gene
lower
compar
wildtyp
depend
cell
line
viru
assembl
like
inhibit
mutant
viru
also
significantli
attenu
anim
model
e
protein
locat
mainli
ergolgi
intermedi
compart
express
alon
sarscov
infect
compris
acid
transmembran
domain
lumen
ntermin
domain
cytoplasm
ctermin
domain
pentamer
cationselect
ion
channel
form
e
protein
transmembran
domain
lipid
bilay
use
nmr
hma
shown
bind
two
site
insid
lumen
channel
form
e
transmembran
domain
specif
interact
observ
amilorid
data
effect
compound
sarscov
replic
avail
yet
howev
hma
amilorid
inhibit
replic
two
coronavirus
human
coronaviru
mous
hepat
viru
cell
cultur
ec
mm
mm
respect
compound
effect
replic
edelet
mous
hepat
viru
confirm
e
protein
target
picornavirida
famili
positivesens
rna
virus
contain
numer
human
pathogen
caus
poliomyel
myocard
mening
hepat
common
cold
diseas
coxsackieviru
respons
human
myocard
case
antivir
treatment
current
avail
picornavir
infect
genom
rna
contain
viral
peptid
vpg
coval
link
end
rna
replic
occur
synthesi
complementari
rna
strand
catalys
viral
rnadepend
rna
polymeras
pol
vpg
serv
primer
harrison
et
al
shown
amilorid
deriv
nethylnisopropyl
amilorid
eipa
fig
hma
benzamil
fig
inhibit
replic
cell
cultur
antivir
effect
amilorid
eipa
inhibit
rna
replic
two
individu
amino
acid
substitut
pol
confer
resist
viru
compound
subsequ
vitro
studi
demonstr
amilorid
eipa
inhibit
enzymat
activ
pol
affect
vpgprime
initi
elong
step
rna
synthesi
amilorid
act
competit
inhibitor
compet
incom
nucleotid
mg
bind
activ
site
enzym
howev
mark
differ
rank
order
compound
inhibit
pol
vitro
eipa
amilorid
benzamil
hma
ec
mm
mm
mm
mm
respect
rna
elong
assay
inhibit
viru
replic
cell
cultur
eipa
hma
benzamil
amilorid
ec
mm
mm
mm
mm
respect
ev
gazina
unpublish
two
potenti
reason
discrep
although
pol
target
amilorid
eipa
addit
target
rule
benzamil
hma
exampl
protein
transmembran
protein
similar
viral
ion
channel
protein
describ
might
inhibit
hma
benzamil
altern
may
larg
differ
intracellular
accumul
compound
hma
uniqu
among
antivir
compound
abil
inhibit
differ
type
protein
produc
virus
differ
famili
importantli
inhibit
virus
antivir
treatment
current
avail
ie
sarscov
target
protein
target
exist
antivir
therapi
ie
vpu
hcv
unfortun
hma
much
higher
potenc
blocker
cellular
na
h
exchang
inhibitor
viral
protein
rule
antivir
drug
howev
develop
suffici
potent
specif
hcv
progress
clinic
trial
clearli
demonstr
amilorid
deriv
use
start
point
antivir
drug
develop
structureact
studi
sarscov
e
pol
may
also
produc
potent
specif
antivir
drug
futur
wherea
antivir
activ
acylguanidin
dengu
virus
yet
demonstr
current
clear
whether
antivir
action
hma
hcv
sarscov
blockad
ion
channel
form
vpu
e
respect
inhibit
function
protein
work
requir
elucid
mechan
activ
acylguanidin
viral
transmembran
protein
competit
inhibit
viral
enzym
pol
amilorid
deriv
surpris
light
previou
find
amilorid
act
competit
inhibitor
sever
cellular
protein
kinas
cholinesteras
serin
proteas
viral
enzym
may
therefor
ad
list
protein
inhibit
compound
futur
